Eli Lilly and Company enters the final week of September with the short rebuild that defined August now visibly unwinding — a clean reversal from the picture painted a week ago.
The covering is the headline data point this week. Short interest dropped 2.9% over the past five trading days to 8.3 million shares, or 0.93% of free float. That follows the previous note's observation that the rebuild had merely "paused at the top." It has now turned. The peak came around September 14-15, when shorts held close to 8.55 million shares. From that level, covering has been orderly and consistent across each session. The prior note's question — "one-day wobble or second covering cycle?" — is getting an answer. Notably, this unwind brings shorts back toward levels last seen in late August, before the mid-September rebuild began. The lending market adds no drama. Availability remains essentially unlimited, with 630 million shares in lending pools and a cost to borrow at just 0.36% — down 14% on the week and 32% over the past month. There is no squeeze dynamic. There is no friction. The short covering reflects choice, not necessity.
Options traders are equally unbothered. The put/call ratio is 1.20, almost exactly in line with its 20-day average of 1.20, and the z-score is effectively zero. This is the flattest options positioning reading in weeks. Through August, the PCR ran well above 1.27 as traders stacked on downside protection — that hedging has now been absorbed. The stock's next earnings date is October 29, and options markets are not yet pricing in any meaningful pre-event skew. At 1.20, the PCR remains elevated in absolute terms relative to the broader market, which is simply the structural reality for a stock with Lilly's valuation — but relative to its own recent range, the positioning is neutral.
The Street has grown more constructive at the margin. Guggenheim raised its price target from $1,273 to $1,284 this week while keeping a Buy rating, and TD Cowen reiterated Buy with a $1,250 target. Both are directionally supportive, though targets from both sit below the current price of $1,170 — meaning even the bulls are not wildly ahead of where the stock trades. The consensus mean target is $1,325, implying roughly 13% upside from here. The main bull case rests on the obesity franchise and the donanemab Alzheimer's opportunity. The bear case centers on Foundayo's sluggish uptake, which has forced analysts to trim near-term sales estimates. HSBC, which maintains a Reduce rating, raised its target to $940 — a level 20% below the current print — reflecting genuine scepticism about valuation rather than pipeline. Factor scores offer modest comfort to bulls: EPS surprise ranks in the 75th percentile, the analyst recommendation differential ranks 93rd percentile, and the short score of 30.9 places Lilly firmly in low-conviction-short territory.
The week's price action supports the covering narrative. LLY gained 3.0% over five sessions to close at $1,170, outpacing JNJ's 0.7% and modestly lagging MRK's 5.0%. The month-to-date picture is softer: down 6.8%, which is the context that likely prompted the August-into-September short rebuild in the first place. Insider data adds little signal this week. Four directors received small compensation grants on September 21 totalling less than $45,000 combined — routine compensation mechanics, not conviction purchases. The only open-market print of note in the past 30 days was an EVP sale of 6,500 shares in August under a pre-arranged 10b5-1 plan. Net insider share activity over the past 90 days is -13,500 shares, driven almost entirely by that planned sale rather than discretionary activity.
With earnings five weeks out on October 29, the next meaningful read on Lilly will be whether the short covering continues through the first half of October or stalls again as traders re-establish hedges ahead of the print — and whether Foundayo data points emerge to resolve the central debate between a $940 bear target and the $1,600 that remains on the table from Citi.
See the live data behind this article on ORTEX.
Open LLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
